Daily online MRI for improving radiotherapy precision

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on developing a new imaging approach using magnetic resonance imaging (MRI) to enhance the accuracy of radiotherapy for patients with adenocarcinoma. By integrating MRI with a radiotherapy machine, the study aims to create high-quality images that can better differentiate between tumor and normal tissue, reducing unnecessary radiation exposure. The research will involve both patient and non-patient volunteers to optimize imaging techniques and establish workflows for clinical application. The ultimate goal is to improve treatment adaptation and quality assurance in radiotherapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All volunteers must undergo and satisfy MRI safety screening
* Non-patient volunteers must have no known (or suspected) significant medical condition and be 18 years of age
* Patient volunteers must have histologically confirmed invasive carcinoma of the tumour/target sites listed in this protocol and be under the care of a Clinical Oncologist at the Royal Marsden NHS Foundation Trust or The Christie NHS Foundation Trust and patients be planned to receive radiotherapy to target site to be imaged
* All volunteers must be willing and able to provide informed consent/assent for the study
* Paediatric patient volunteers between the ages of 3 and 18 years, will have consent provided by his or her legal guardian who is 18 years of age
* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

Exclusion Criteria:

Any conditions that would be a contra-indication to MRI including:

* Failure to satisfy the MRI safety screening
* Implanted pacemakers and/or pacing wires
* Cochlear implants
* Programmable hydrocephalus shunts
* Implanted neurostimulation systems
* Implanted drug infusion pumps
* Ferromagnetic implants And additional conditions that may place volunteers at increased risk from MRI procedures including:
* Known susceptibility to seizures or migraines
* Fever, reduced thermal regulatory capabilities or increased sensitivity to raised body temperature (for example pregnant women)

Where it's running

• The Royal Marsden NHS Foundation Trust
  Sutton, Surrey, United Kingdom Recruiting

Study contacts

• Principal investigator: Robert Huddart — Institute of Cancer Research, United Kingdom
• Study coordinator: Greta Bucinskaite
• Email: greta.bucinskaite@rmh.nhs.uk
• Phone: +44 20 3186 5157

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Methionine-Reduced Diet in Solid Tumors (early-phase)

  A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.

  Recruiting Early Phase 1 University of California, Irvine · Orange, California · NCT07628634

• TriAdeno and N-803 vaccine in early prostate cancer on active surveillance

  A vaccine combo called TriAdeno plus the N-803 drug is being tested to see if it can help slow or stop growth in men with early-stage, low- to intermediate-risk prostate cancer who are being watched rather than treated right away.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07574541

• LM-302 with tislelizumab plus chemotherapy for stomach and gastroesophageal junction cancer

  This phase 3 study tests whether LM-302 added to tislelizumab is better or safer than tislelizumab with chemotherapy in patients with newly diagnosed, unresectable or metastatic stomach/GEJ adenocarcinoma that express CLDN18.2.

  Recruiting Phase 3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Hefei, Anhui and 105 other locations · NCT07385703

• Relacorilant with nab-paclitaxel and gemcitabine for metastatic pancreatic adenocarcinoma

  This trial tests whether adding relacorilant to standard chemotherapy (nab-paclitaxel plus gemcitabine) helps people with previously untreated metastatic pancreatic adenocarcinoma.

  Recruiting at 19 sites Phase 2 Corcept Therapeutics · Scottsdale, Arizona and 19 other locations · NCT07259317

• Long-term clinical and tissue data collection for people with thoracic cancers

  This project will collect medical records, imaging, quality-of-life information, and tissue/blood samples over time from adults with thoracic cancers to try to find factors that predict outcomes.

  Recruiting at 11 sites Dutch Society of Physicians for Pulmonology and Tuberculosis · Ede, Gelderland and 22 other locations · NCT06996249

• Multimodal ablation with Tislelizumab, lenvatinib and TACE for unresectable primary liver cancer

  This trial will test whether combining multimodal ablation with Tislelizumab (a PD‑1 antibody), lenvatinib, and TACE helps people with unresectable primary liver cancer.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT06794073

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.